**Sanofi Commits to $20 Billion U.S. Investment Through 2030**
French pharmaceutical giant Sanofi announced plans to invest at least $20 billion in the United States by 2030. The investment will include a significant boost in research and development efforts, along with substantial funding directed toward expanding U.S.-based manufacturing operations.
The move aligns with a broader trend among major pharmaceutical companies, including Roche, Johnson & Johnson, and Novartis, who are responding to increased calls for domestic pharmaceutical production.
“Sanofi’s 13,000 U.S.-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas,” said Paul Hudson, CEO of Sanofi. “Our expected investments in the U.S. will be substantial and will help ensure the production of key medicines in the U.S.”
In particular, Sanofi aims to significantly scale its R&D expenditure in the U.S. and expand its manufacturing footprint through both direct investments in Sanofi facilities and partnerships with domestic manufacturers. These initiatives will strengthen the company’s ability to produce essential medicines within the country and accelerate scientific advancement.
*Photo courtesy of Sanofi.*
